The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome

The document discusses the potential use of Tirzepatide, a dual GLP-GIP receptor agonist, in managing Polycystic Ovary Syndrome (PCOS). Tirzepatide has been shown to control blood glucose concentrations, stimulate insulin secretion, suppress glucagon release, increase insulin sensitivity, and contribute to weight reduction. It has been licensed for the treatment of type 2 diabetes and may be valuable in managing PCOS in obese patients with metabolic syndrome. However, it may not benefit those of normal weight. A study found that 76% of women with PCOS lost more than 5% of their weight when administered a similar drug, liraglutide, over 20 weeks. Tirzepatide has potential side effects and interacts with certain drugs. It is not advised for patients with a history of thyroid cancer or gastroparesis. Further clinical trials are needed to confirm the efficacy and safety of Tirzepatide in treating PCOS. The document does not provide the number of participants involved in the study.